Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-07-2014 | Award Amount: 20.85M | Year: 2014
COMPARE aims to harness the rapid advances in molecular technology to improve identification and mitigation of emerging infectious diseases and foodborne outbreaks. To this purpose COMPARE will establish a One serves all analytical framework and data exchange platform that will allow real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. clinical, epidemiological data) in an integrated inter-sectorial, interdisciplinary, international, one health approach. The framework will link research, clinical and public health organisations active in human health, animal health, and food safety in Europe and beyond, to develop (i) integrated risk assessment and risk based collection of samples and data, (ii) harmonised workflows for generating comparable sequence and associated data, (iii) state-of-the-art analytical workflows and tools for generating actionable information for support of patient diagnosis, treatment, outbreak detection and -investigation and (iv) risk communication tools. The analytical workflows will be linked to a flexible, scalable and open-source data- and information platform supporting rapid sharing, interrogation and analysis of sequence-based pathogen data in combination with other associated data. The system will be linked to existing and future complementary systems, networks and databases such as those used by ECDC, NCBI and EFSA. The functionalities of the system will be tested and fine tuned through underpinning research studies on priority pathogens covering healthcare-associated infections, food-borne disease, and (zoonotic) (re-) emerging diseases with epidemic or pandemic potential. Throughout the project, extensive consultations with future users, studies into the barriers to open data sharing, dissemination and training activities and studies on the cost-effectiveness of the system will support future sustainable user uptake.
Vernet G.,Fondation Merieux
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | Year: 2011
In view of the increasing use of pneumococcal vaccines, especially in the developing world, there is a need for appropriate diagnostics to understand the aetiology of pneumonia, to define the burden of pneumococcal disease, and to monitor vaccine efficacy and effectiveness. This article summarizes a meeting on the diagnosis, detection and serotyping of pneumococcal disease organized by PATH and Fondation Mérieux (18-20 October 2009, Fondation Mérieux Conference Centre, Les Pensières, France). Workers and experts met to discuss the gaps in the microbiology-based diagnosis of Streptococcus pneumoniae disease, with special emphasis on pneumonia. The meeting was designed to evaluate the state of the art of pneumococcal diagnostics and serotyping methodologies, identify research and development needs, and propose new guidelines to public health authorities to support the introduction of vaccines. Regarding detection, the main recommendations were to encourage chest X-rays and antigen detection in urine. Large-scale studies are needed to evaluate the diagnostic utility of test algorithms that associate chest X-rays, antigen detection in urine, S. pneumoniae quantitative PCR in nasopharyngeal aspirates and sputum, and C-reactive protein or procalcitonin measurement in blood. Efforts should be focused on proteomics to identify pneumococcus-specific antigens in urine or host markers in blood expressed during pneumonia. It was recommended to develop S. pneumoniae typing capacities, to understand the epidemiology of pneumococcal disease, and to evaluate vaccine effectiveness. Simple and effective approaches are encouraged, and new technologies based on beads, microarrays or deep sequencing should be developed to determine, in a single test capsular serotype, resistance profile and genotype. © 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.
Vernet G.,Fondation Merieux |
Altmann D.M.,Imperial College London |
Doumbo O.,Malaria Research and Training Center |
Bhutta Z.A.,Aga Khan University |
And 2 more authors.
Emerging Infectious Diseases | Year: 2014
Antimicrobial drug resistance is usually not monitored in under-resourced countries because they lack surveillance networks, laboratory capacity, and appropriate diagnostics. This accelerating problem accounts for substantial number of excess deaths, especially among infants. Infections particularly affected by antimicrobial drug resistance include tuberculosis, malaria, severe acute respiratory infections, and sepsis caused by gram-negative bacteria. Nonetheless, mapping antimicrobial drug resistance is feasible in under-resourced countries, and lessons can be learned from previous successful efforts. Specimen shipping conditions, data standardization, absence of contamination, and adequate diagnostics must be ensured. As a first step toward solving this problem, we propose that a road map be created at the international level to strengthen antimicrobial resistance surveillance in under-resourced countries. This effort should include a research agenda; a map of existing networks and recommendations to unite them; and a communication plan for national, regional, and international organizations and funding agencies.
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2009.9.1 | Award Amount: 2.96M | Year: 2011
There is widespread agreement that ICT services have the potential to play a major role in furthering social development in developing economies such as those in Africa. However, while there is a great deal of potential and opportunity, the amount and scope of actual mobile ICT services currently in existence in African countries is very limited.\n\nThe Mobile Web for Social Development Roadmap, recently published as a result of the FP7 Digital World Forum project, makes it clear that realizing the potential of mobile ICT services requires addressing two major types of challenges:\n1. The leveraging of content that is locally relevant; and\n2. The removal of a range of access barriers, notably limitations related to access channels, literacy, and languages.\n\nVOICES intends to take a major step forward in realizing the potential of mobile ICT services particularly in the African context and resolve key challenges outlined in the Mobile Web for Social Development Roadmap. To this end, the objectives of VOICES are to deliver:\n Open and wider access: VOICES will improve voice-based access to content and mobile ICT services by building a toolbox for the development of voice services.\n Integration of Local Community Radios and ICT.\n Better support of languages: It will deliver tool support and methodology for under researched and under resourced African languages.\n Long-term sustainability: To ensure the local adoption and exploitation of the VOICES tools and methods beyond the project, it will provide a sustainable architecture.\n Faster uptake: VOICES will furthermore enhance uptake by delivering a mobile training lab that offers capacity building for local partners.\n\nVOICES will demonstrate the fitness of its results for adaptation to the African context by extensive local pilots and associated community building, namely through the focus on health services in Senegal, and agricultural and regreening knowledge sharing in the Sahel countries.
Girard M.P.,French National Academy of Medicine |
Picot V.,Fondation Merieux |
Longuet C.,Fondation Merieux |
Nabel G.J.,Sanofi S.A.
Vaccine | Year: 2013
The Cent Gardes Conference on HIV Vaccines took place on November 5-7, 2012 at the Fondation Mérieux Conference Center, Annecy, France. The aim of the meeting was to review the B cell response to human immunodeficiency virus-1 (HIV-1) infection and immunization, from broadly neutralizing antibodies (bnAbs) to non-neutralizing antibodies (n-nAbs). The production of cross-reactive bnAbs is one of the greatest challenges in HIV-1 vaccine development. In natural HIV infection, bnAbs are observed in only a minority of infected individuals and take a few years to develop. This report presents a comprehensive review of how these Abs arise, the possible role of viral evolution, and the activation and maturation requirements of B cell lines that lead to their production. Passive immunization with bnAbs provides efficient, cross-clade protection against simian/human immunodeficiency chimeric virus (SHIV) challenges in nonhuman primates. Despite many efforts to design immunogens that elicit them by active immunization, no immunogen other than HIV itself has yet been able to elicit a bnAb response. For this reason, innovative approaches are under investigation, including their production in the body through a gene delivery approach, vector immunoprophylaxis. © 2013 Elsevier Ltd.